Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 163
Filter
1.
Nursing ; 51(10): 18-29, 2021 Oct 01.
Article in English | MEDLINE | ID: mdl-34580258

ABSTRACT

ABSTRACT: The second of a two-part series, this article describes eight recently approved drugs, including the first drug approved for the treatment of SARS-CoV-2, a first-in-class HIV attachment inhibitor, and a new intravenous injection indicated for the treatment of acute pain in adults for whom other treatments are ineffective.


Subject(s)
Drug Approval , Adenosine Monophosphate/analogs & derivatives , Adenosine Monophosphate/therapeutic use , Alanine/analogs & derivatives , Alanine/therapeutic use , Amisulpride/therapeutic use , Carbamates/therapeutic use , Cephalosporins/therapeutic use , Chlorophenols/therapeutic use , Drug Combinations , Fumarates/therapeutic use , Humans , Indans/therapeutic use , Organophosphates/therapeutic use , Oxadiazoles/therapeutic use , Piperazines/therapeutic use , Spiro Compounds/therapeutic use , Tetrazoles/therapeutic use , Thiophenes/therapeutic use , Tromethamine/therapeutic use , United States , United States Food and Drug Administration , COVID-19 Drug Treatment , Cefiderocol
2.
Nursing ; 51(2): 36-44, 2021 Feb 01.
Article in English | MEDLINE | ID: mdl-33953097
4.
Nursing ; 50(2): 31-38, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31895198
7.
Nursing ; 49(8): 24-32, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31268951
10.
Nursing ; 48(10): 32-43, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30192268

ABSTRACT

This article discusses eight drugs recently approved by the FDA, including their indications and contraindications, precautions, dosage, and nursing considerations. The article also includes summary charts on 14 recently approved antineoplastic drugs and four drugs approved for rare disorders.


Subject(s)
Drug Approval , Acetates/therapeutic use , Boronic Acids/therapeutic use , Drug Combinations , Fluoroquinolones/therapeutic use , Humans , Meropenem , Metronidazole/analogs & derivatives , Metronidazole/therapeutic use , Nitroimidazoles/therapeutic use , Parathyroid Hormone-Related Protein/therapeutic use , Peptides/therapeutic use , Prostaglandins F, Synthetic/therapeutic use , Quinazolines/therapeutic use , Thienamycins/therapeutic use , United States , United States Food and Drug Administration
11.
Consult Pharm ; 33(4): 188-198, 2018 Apr 01.
Article in English | MEDLINE | ID: mdl-29609697

ABSTRACT

Five new drugs marketed within the last year, which are used for medical problems often experienced by the elderly, have been selected for consideration in this review. The uses and most important properties of these agents are discussed, and a rating for each new drug is determined using the New Drug Comparison Rating system developed by the author (DAH). Advantages, disadvantages, and other important information regarding each new drug are identified and used as the basis for determining the rating. The drugs include an anticoagulant, an antiparkinson agent, an agent for tardive dyskinesia, an agent for psoriasis, and an agent for constipation. The drugs reviewed are betrixaban, safinamide mesylate, valbenazine tosylate, guselkumab, and plecanatide.


Subject(s)
Drug Approval , Aged , Alanine/analogs & derivatives , Alanine/therapeutic use , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Anticoagulants/therapeutic use , Antiparkinson Agents/therapeutic use , Benzamides/therapeutic use , Benzylamines/therapeutic use , Constipation/drug therapy , Humans , Natriuretic Peptides/therapeutic use , Psoriasis/drug therapy , Pyridines/therapeutic use , Tardive Dyskinesia/drug therapy , Tetrabenazine/analogs & derivatives , Tetrabenazine/therapeutic use , Valine/analogs & derivatives , Valine/therapeutic use
12.
Consult Pharm ; 32(5): 258-268, 2017 May 01.
Article in English | MEDLINE | ID: mdl-28483006

ABSTRACT

Five new drugs marketed within the last year that are used for medical problems often experienced by the elderly have been selected for consideration in this review. The uses and most important properties of these agents are discussed, and a rating for each new drug is determined using the New Drug Comparison Rating system developed by the author (DAH). Advantages, disadvantages, and other important information regarding each new drug are identified and used as the basis for determining the rating. The drugs include two antidiabetic agents, an agent for gout, an antipsychotic agent, and a drug for dry eye disease.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Antipsychotic Agents/therapeutic use , Drugs, Investigational/therapeutic use , Gout Suppressants/therapeutic use , Hypoglycemic Agents/therapeutic use , Anti-Inflammatory Agents/adverse effects , Antipsychotic Agents/adverse effects , Drugs, Investigational/adverse effects , Dry Eye Syndromes/drug therapy , Gout Suppressants/adverse effects , Humans , Hypoglycemic Agents/adverse effects , Insulin, Long-Acting/therapeutic use , Peptides/therapeutic use , Phenylalanine/analogs & derivatives , Phenylalanine/therapeutic use , Piperidines/therapeutic use , Sulfones/therapeutic use , Thioglycolates/therapeutic use , Triazoles/therapeutic use , Urea/analogs & derivatives , Urea/therapeutic use
13.
Consult Pharm ; 31(4): 186-98, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27056355

ABSTRACT

Six new drugs marketed within the last year, which are used for medical problems often experienced by the elderly, have been selected for consideration in this review. The uses and most important properties of these agents are discussed, and a rating for each new drug is determined using the New Drug Comparison Rating (NDCR) system developed by the author. Advantages, disadvantages, and other important information regarding the new drug are identified and used as the basis for determining the rating. The drugs include a hypnotic, an anticoagulant, two drugs for heart failure, and two drugs to reduce low-density lipoprotein cholesterol.


Subject(s)
Anticholesteremic Agents/therapeutic use , Anticoagulants/therapeutic use , Heart Failure/drug therapy , Hypnotics and Sedatives/therapeutic use , Aged , Drug Approval , Humans , United States
16.
Consult Pharm ; 30(4): 192-208, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25893698

ABSTRACT

Six new drugs approved within the last two years, which are used for medical problems often experienced by the elderly, have been selected for consideration in this review. The uses and most important properties of these agents are discussed, and a rating for each new drug is determined using the New Drug Comparison Rating system developed by the author. Advantages, disadvantages, and other important information regarding the new drug are identified and used as the basis for determining the rating. The drugs include two antidiabetic agents, one bronchodilator, one antidepressant, one for erectile dysfunction, and one for menopause-associated conditions.


Subject(s)
Drug Approval , Benzhydryl Compounds/therapeutic use , Estrogens, Conjugated (USP)/administration & dosage , Glucagon-Like Peptide 1/analogs & derivatives , Glucagon-Like Peptide 1/therapeutic use , Glucosides/therapeutic use , Humans , Indoles/administration & dosage , Piperazines/therapeutic use , Pyrimidines/therapeutic use , Quinuclidines/therapeutic use , Sulfides/therapeutic use , Vortioxetine
SELECTION OF CITATIONS
SEARCH DETAIL